Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Qualigen Therapeutics Inc QLGN

Healthcare Biotechnology
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.


NDAQ:QLGN - Post by User

Qualigen Therapeutics Inc > QLGN ...... Cya .... has to hold $1.00 or .....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(57)
•••
Comment by Iseneschalon Apr 12, 2022 2:24pm
35 Views
Post# 34597790

RE:QLGN ...... Cya .... has to hold $1.00 or .....

RE:QLGN ...... Cya .... has to hold $1.00 or .....
Iseneschal wrote: It's going to fill the sub 41.00 gap down to $0.77


 Cheers 1


Worth a repeat....did exactly what I thought. It's called "filling the gap"

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities